China clamps down on investigator-initiated trials amid US calls for faster research
China is tightening rules on investigator-initiated clinical trials, a practice that has driven its rapid biomedical growth but raised safety concerns.
China’s regulatory authorities are now imposing tighter controls on investigator-initiated clinical trials, a model that previously allowed researchers to start studies without prior sign-off from the National Medical Products Administration. This framework has been credited with propelling China ahead of the United States in research funding, patent filings and the number of trials, while also encouraging doctors to take part in drug innovation and contributing billions of dollars in new medicine sales.
Critics argue that the lack of rigorous review has created gaps in patient safety, transparency and intellectual-property safeguards. The recent tightening reflects growing scrutiny of those shortcomings. Observers suggest the United States could learn from the speed of China’s system, but must also address the risks highlighted by the new regulations.
Why it matters
Regulatory changes could affect the speed and safety of new drug development worldwide.
In this story